Post-earnings recap
Reported
Wed, Jul 29, 2026
EPS actual
$0.86
EPS est.
$0.83
EPS surprise
+3.49%
1-day move
-0.04%
Boston Scientific reported an EPS of $0.86, beating expectations by 3.49%. However, the stock reacted slightly negatively, down 0.04%. The lack of revenue data and management commentary may have contributed to the muted stock performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.86 | N/A | +3.49% |
| Revenue | N/A | N/A | — |
No transcript is on record, so the analysis is based solely on numerical results.
Boston Scientific Corporation (BSX) is a leading medical device company that develops and manufactures a wide range of products used in various medical specialties, including cardiology, urology, and endoscopy. With a market cap of $77 billion, the company plays a crucial role in the healthcare sector, particularly as demand for innovative medical solutions continues to grow.
Last quarter
In Q1-2026, Boston Scientific reported an EPS of $0.80, matching analyst expectations and resulting in a positive stock reaction of nearly 9% the following day. The company has consistently beaten EPS estimates over the past several quarters.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+5.49%
Avg 1-day reaction
+0.57%
Overall, investors are optimistic about Boston Scientific's upcoming earnings report, especially given its strong track record of beating EPS estimates. However, there are concerns about potential revenue growth amidst increasing competition in the healthcare equipment sector.
Bull case
If Boston Scientific continues its trend of exceeding EPS estimates and shows robust revenue growth, it could signal strong demand for its products, leading to a positive stock reaction.
Bear case
On the other hand, if the company fails to meet expectations or provides cautious guidance regarding future growth, it could lead to a significant decline in stock price.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
Given the company's history of beating EPS estimates, this number will be crucial for determining investor sentiment and stock performance.
Q2
How is revenue growth tracking in key markets?
Understanding revenue growth in emerging markets will provide insight into the company's future potential and competitive positioning.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.5%
Why consensus could be wrong
The Street may be underestimating the potential for Boston Scientific to exceed EPS expectations due to its strong product pipeline and market expansion strategies.
Supporting evidence
The company has a 100% EPS beat rate over the last several quarters, indicating consistent performance.
Options pricing suggests a lower expected move compared to historical averages, which may not reflect the company's growth potential.
Key risk
If the company reports an EPS significantly above $0.80, it could challenge the current cautious sentiment in the market.
Pre-commit to what would confirm each case.
The core thesis revolves around Boston Scientific's ability to maintain its growth trajectory and profitability in a competitive healthcare market.
Bull confirmed if
A reported EPS of $0.85 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.75 would confirm the bear case, suggesting potential issues with profitability.
What the market is pricing for the move.
Implied Move
±1.36%
Historical Avg
±5.1%
The options market is pricing in a modest move of about 1.36%, suggesting that traders expect relatively stable performance around the earnings announcement.
Options are pricing ±1.4% while BSX has averaged ±5.1% over the last 8 prints — setup is pricing cheap.
ATM IV
0.4%
30d HV
59.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Boston Scientific beats expectations, history suggests a positive stock reaction of around +0.45%, confirming strong demand for its products.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.
Miss
A miss could lead to a significant decline, with historical data suggesting an average drop of around -17.59% following disappointing earnings.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
11
5 buys·6 sells
Members
3
House + Senate
Est. Notional
$123,011.00–$370,000.00
disclosed dollar ranges
Most Active Members
6 trades
The lines on the call that would change the story.
Mixed
4 trades
Net selling
1 trade
Net selling
Recent Transactions
Traded Sep 9, 2026 · disclosed Sep 25, 2026
$50,001.00–$100,000.00
Traded Sep 4, 2026 · disclosed Sep 25, 2026
$50,001.00–$100,000.00
Traded Sep 3, 2026 · disclosed Sep 25, 2026
$1,001.00–$15,000.00
Traded Aug 31, 2026 · disclosed Sep 25, 2026
$15,001.00–$50,000.00
Traded Aug 18, 2026 · disclosed Sep 10, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.